Reply to Woodie et al, “Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-α inhibitors compared with the general population: A population-based analysis using TriNetX”

Journal of the American Academy of Dermatology 2026

View at publisher

Authors: Tiago Torres, Andrew Blauvelt, Bruce E Strober, Peter C.M. van de Kerkhof, Guy S. Eakin, Kevin Winthrop, Joel M. Gelfand

DOI: 10.1016/j.jaad.2025.12.129

Cited by: 2

References: 3

Fields of Study & Subjects

Psoriasis: Treatment and Pathogenesis Tuberculosis Research and Epidemiology Spondyloarthritis Studies and Treatments

References 3